Plus Therapeutics, Inc. (NASDAQ:PSTV) Sees Significant Increase in Short Interest

Plus Therapeutics, Inc. (NASDAQ:PSTV) was the recipient of a large growth in short interest in the month of June. As of June 15th, there was short interest totalling 205,300 shares, a growth of 19.8% from the May 31st total of 171,300 shares. Approximately 3.7% of the company’s shares are short sold. Based on an average daily trading volume, of 75,300 shares, the days-to-cover ratio is presently 2.7 days.

Plus Therapeutics Trading Up 1.1 %

NASDAQ PSTV traded up $0.02 during trading hours on Tuesday, hitting $1.52. The company’s stock had a trading volume of 15,341 shares, compared to its average volume of 54,331. The company has a market capitalization of $8.65 million, a PE ratio of -0.50 and a beta of 0.54. Plus Therapeutics has a 52 week low of $0.97 and a 52 week high of $3.21. The company’s 50-day simple moving average is $2.01 and its two-hundred day simple moving average is $1.94.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.34. The business had revenue of $1.68 million during the quarter. Plus Therapeutics had a negative return on equity of 805.57% and a negative net margin of 193.49%. During the same period in the previous year, the company posted ($2.10) earnings per share.

Insiders Place Their Bets

In other news, CEO Marc H. Hedrick bought 12,255 shares of the stock in a transaction dated Wednesday, May 8th. The shares were bought at an average cost of $2.04 per share, with a total value of $25,000.20. Following the completion of the transaction, the chief executive officer now directly owns 12,425 shares of the company’s stock, valued at $25,347. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders have purchased 26,961 shares of company stock valued at $55,000. 2.32% of the stock is currently owned by company insiders.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.